Innovation
Innovation means more moments like this
We're driven by our deep understanding of the root causes of disease, focusing our R&D in areas like cancer, HIV, and respiratory diseases where we can make the most meaningful difference for people.
Investors
We announced our second quarter 2026 results on Tuesday, 28 July.
Press releases
- Jemperli (dostarlimab-gxly) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
- Blenrep assigned permanent billing code, supporting timely access for patients with relapsed/refractory multiple myeloma
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK Global links
Visit our Global site for additional features








